Boston Scientific Symbiot
This article was originally published in The Gray Sheet
Executive Summary
Covered stent system for saphenous vein graft disease debuts in Europe following CE mark approval. The self-expanding nitinol stent, which is encased in a thin, porous ePTFE polymer membrane, decreases plaque embolization during the stenting procedure and reduces restenosis, according to the firm. Symbiot III, a 700-patient, multicenter, U.S. randomized clinical trial is underway, and FDA approval is expected in early 2004...